Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Inhibrx Biosciences, Inc. (INBX)

Inhibrx Q2 net loss widens to $36.7 million; no revenue in the quarter

Negative Impact 3 of 5 earnings Written later

Inhibrx reported second-quarter 2026 results showing a net loss of $36.7 million, or $2.34 per share, compared with $28.7 million, or $1.85 per share, a year earlier. The company recognized no revenue in the quarter, down from $1.3 million in the second quarter of 2025, and higher interest expense on its loan contributed to the larger loss.

Key points

  • Net loss of $36.7 million ($2.34 per share) vs. $28.7 million ($1.85 per share) in Q2 2025
  • No revenue in Q2 2026 vs. $1.3 million in Q2 2025 from the Scithera license transfer
  • R&D expense rose to $23.9 million from $22.3 million; G&A rose to $8.3 million from $6.4 million
  • Cash was $133.3 million at June 30, 2026, and $219.5 million as of August 6, 2026, after $100.0 million was funded under the Oxford loan amendment on July 15, 2026

The filing

CompanyInhibrx Biosciences, Inc. (INBX)
Form8-K, current report
Filed with the SECAug 13, 2026, 4:10 PM ET
Accession number0002007919-26-000044

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.